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We tested the claim that inter-individual CBF variability in Alzheimer’s disease (AD) is sub-
stantially reduced after correction for arterial carbon dioxide tension (PaCO2). Specifically,
we tested whether the variability of CBF in brain of patients with AD differed significantly
from brain of age-matched healthy control subjects (HC).To eliminate the CO2-induced vari-
ability, we developed a novel and generally applicable approach to the correction of CBF
for changes of PaCO2 and applied the method to positron emission tomographic (PET)
measures of CBF in AD and HC groups of subjects. After correction for the differences of
CO2 tension, the patients with AD lost the inter-individual CBF variability that continued
to characterize the HC subjects. The difference (1K 1) between the blood-brain clearances
(K 1) of water (the current measure of CBF) and oxygen (the current measure of oxygen
clearance) was reduced globally in AD and particularly in the parietal, occipital, and tempo-
ral lobes. We then showed that oxygen gradients calculated for brain tissue were similar
in AD and HC, indicating that the low residual variability of CBF in AD may be due to low
functional demands for oxidative metabolism of brain tissue rather than impaired delivery
of oxygen.




Cerebral blood flow (CBF) measures vary greatly among healthy
individuals at rest (Ito et al., 2004; Aanerud et al., 2012). Some of
this inter-individual variability may arise from intra-individual
temporal fluctuations in CBF regulation, such as arterial CO2
tension changes or varying functional demands within each sub-
ject. At subject level, intra-individual measures of CBF variability
also provide the basis for current functional brain mapping tech-
niques with [15O]water in PET, and also with BOLD signals
in functional Magnetic Resonance Imaging (fMRI). The inter-
individual CBF variation among healthy people and patients
with neurodegenerative disorders such as Alzheimer’s disease can
therefore arise from separate classes of variation: (i) Individual
transient fluctuations varying with time constants of seconds,
minutes, or hours, and (ii) Intrinsic variability among the sub-
jects’ ability to regulate blood flow. Separating these classes of
variation becomes crucial in determining pathological condi-
tions affecting either (i) or (ii) and in determining their causal
relationship.
In this work we (A) develop a new method for estimating the
change in CBF in response to PaCO2 (which is a well described
regulator of CBF), and (B) we show that once the CO2 varia-
tion is factored out, there remains very little variation in a group
of patients suffering from AD compared to a group of healthy
aged control subjects. To analyze possible links between the loss of
variability in AD and brain metabolism, we also (C) analyze the
relationship between CBF and oxygen consumption CMRO2.
FACTORS INFLUENCING CBF VARIABILITY
Some factors influencing the variability of CBF are known, includ-
ing arterial blood pressure changes and variations of the arterial
carbon dioxide tension (PaCO2), but the mechanisms of global
and regional flow-metabolism coupling in response to changes of
brain functional demands, embodied in part in the so-called neu-
rovascular control unit, involving both microvessels and astrocytic
endfeet, are unclear, despite many years of study (Berne et al., 1981;
Kontos, 1981; Nicolakakis and Hamel, 2011; Peterson et al., 2011).
Changes in the cerebral microvascular endothelium may be
implicated in the pathogenesis of neurodegenerative diseases and
possibly even in the onset of AD, as regulatory deficiency can cause
cerebral hypoperfusion which may precede or contribute to AD
(Nagata et al., 2000; Farkas and Luiten, 2001; Grammas et al.,
2011; van Beek et al., 2012). Thus, the evidence of amyloid-related
pathogenesis of AD may bear directly on endothelial function
(Deane et al., 2003; Grammas et al., 2011) and indirectly on
the transient control of CBF, although the order of cause and
effect remains uncertain (Chen et al., 2011). Indeed, the findings
suggest that loss of vasomotor dynamics may contribute to the
hypoperfusion, if the neurovascular mediators of functional flow
variability are uncoupled from the response to CO2 (Iliff et al.,
2003).
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PRESSURE AUTOREGULATION OF CBF
In the following, we distinguish between purely vascular reactiv-
ity, which includes pressure autoregulation and CO2 response,
on one hand, and the metabolic or functional reactivity, on the
other (Nagata et al., 2000). Blood pressure autoregulation serves to
minimize the effect of arterial blood pressure changes on cerebral
blood flow. The mechanism is uncertain, but it differs fundamen-
tally from the process that elicits changes of cerebral blood flow
in response to changes of CO2. Thus, situations exist in which
one of the two mechanisms is preserved and the other is impaired
(Lauritzen, 1984; Panerai et al., 1999).
With transcranial laser Doppler technique in patients with mild
AD, Claassen et al. found little impairment of cerebral autoreg-
ulation, but generally lower variability of CBF velocity (CBFV;
Claassen et al., 2009; Claassen and Zhang, 2011). The low vari-
ability was reflected in the average baseline CBFV measure of 38
vs. 55 cm/s in AD vs. HC, although the authors later were unable
to confirm the findings (van Beek et al., 2012). Using PET in AD,
Zazulia et al. (2010) found that cerebral perfusion rates remained
stable with a moderate 14% decline of blood pressure, although
interpretations were complicated by the low blood pressure change
and the use of nicardipine to modify the blood pressure (Claassen
and Zhang, 2011).
CO2 EFFECT ON CBF
The vasoactive response to carbon dioxide was established by
Carl F. Schmidt as early as in 1928 and by the later reports of Kety
and Schmidt on the effects of CO2 inhalation in pilots (Schmidt,
1928; Kety and Schmidt, 1946, 1948), followed by extensive con-
firmation until this date. Evidence suggests that CO2 reactivity is
preserved in human AD (Jagust et al., 1997; Nagata et al., 2000),and
likewise in transgenic mice that overexpress the amyloid precursor
protein (APP; Niwa et al., 2002).
CORRECTIONS FOR CO2 EFFECT
The findings above suggest that the low, but relatively constant
baseline perfusion in AD possibly is related to reduced activity of
the neurovascular mediators of fluctuating functional demands.
Thus, a fundamental loss of functional brain dynamics in AD can
be revealed only when CBF variations related to PaCO2 change
are eliminated. Here, we reveal the degree of reduction of the
variability of CBF remaining after elimination of the CO2 effect.
We use a novel approach to correction for PaCO2 changes, which
corrects both individual and group measures of CBF, in relation
to the average normocapnic PaCO2 and its corresponding CBF.
The method as presented has broad applicability to CBF mea-
surements, regardless of modality, including non-invasive mea-
sures of CO2 (for example with a finger monitor). We used this
novel approach to determine how much of the CBF variability
remained after the reactivity due to variations of PaCO2 was elim-
inated in a group of healthy individuals and a group of patients
with AD.
DELIVERY OF OXYGEN AFTER LOSS OF VARIABILITY
To understand how the loss of CBF variability related to functional
demands in the AD patients, we tested whether the dependence of
oxygen consumption on oxygen delivery to the brain (1K 1) was
affected in brain of the patients with AD.
MATERIALS AND METHODS
The methods used in this study consist of three major parts
1) Derivation of the method used for factoring out the CO2
variability, and how to use it for other studies.
2) Methods pertaining to the acquisition of the data from the AD
and HC subjects.
3) How to combine the CBF and CMRO2 data in order to estimate
the oxygen gradient in the tissue.
CORRECTION FOR CO2 EFFECT
The method used for factoring out the CO2 variability in humans
was developed by modifying the functional relationship of CBF
derived from a primate study, so that it fits well with the human
response to CO2 changes in the blood. The regression for esti-
mating the human parameters was done using previous published
studies. The developed method1 can be generally applied to any
new dataset where normocapnic set-point of mean CBF and mean
CO2 are known.
Estimating the CO2 effect in humans from historic data
The correction factor fC is the relative change that an average base-
line CBF value measured at a standard PaCO2 level undergoes as
a function of a varying PaCO2 in the blood [see equation (8)
below].
Corresponding single subject values of PaCO2 and CBF in
hypo-, normo-, and hypercapnia of humans were extracted from
values reported by Kety and Schmidt (1946, 1948), and digitized
from Figure 2 reported by Ramsay et al. (1993). Normalized frac-
tional values were calculated relative to the mean normal values
presented by Ramsay et al. (1993). For each subject, the rela-
tive fractional hypocapnic and hypercapnic values of PaCO2 were
converted to units of mmHg relative to the mean normocap-
nic PaCO2 tension of 39.5 mmHg. The single subject fractional
CBF response was calculated relative to the normocapnic CBF
value, as listed in Table 1. The relative PaCO2 values and frac-
tional CBF response were used to estimate the correction factor
fC. To do so, we considered several possible model functions of the
data and chose the exponential relation given by Reivich (1964).
In order to model the data for use as a practical correction, we
modified the parameters of the shape of the response curve of
Reivich (1964) to reflect the relative human CBF measures as
function of the PaCO2 variation relative to the mean normo-
capnic PaCO2. The relationship presented as Figure 3 of Reivich
(1964) for rhesus monkeys is a logistic curve in which the lower
limit of hypocapnic CBF is 20.9 mL/100 g/min and the upper limit
of hypercapnic CBF is 113.7 mL/100 g/min. By normalizing to
the average measured baseline CBF of 49.3 mL/100 g/min in the
present study, the relative relationship f rhesusC for rhesus monkeys
became,
f rhesusC = 0.42+
(2.31− 0.42)[
1+ B ekr log10 PaCO2] (1)
1A matlab® subroutine and a CBF image scaling script for the MINC format is freely
distributed by email request to the corresponding author.
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Table 1 | Carbon dioxide reactivity.
PaCO2 mmHg Relative PaCO2 mmHg CBF mL/min 100 g CBF fractional
H C E FH/C FC/C FE/C H C E H/C C/C E/C
Ramsay et al. (1993)
Gray matter 24 38 55 24.9 39.5 57.2 45 73 115 0.62 1.00 1.58
23 38 55 23.9 39.5 57.2 37 50 105 0.74 1.00 2.10
24 41 53 23.1 39.5 51.1 32 47 108 0.68 1.00 2.30
20 40 55 19.8 39.5 54.3 43 68 118 0.63 1.00 1.74
20 42 57 18.8 39.5 53.6 30 51 75 0.59 1.00 1.47
20 38 55 20.8 39.5 57.2 49 52 104 0.94 1.00 2.00
White matter 24 38 55 24.9 39.5 57.2 18 16 28 1.13 1.00 1.75
23 38 55 23.9 39.5 57.2 12 20 35 0.60 1.00 1.75
24 41 53 23.1 39.5 51.1 15 25 39 0.60 1.00 1.56
20 40 55 19.8 39.5 54.3 10 21 39 0.48 1.00 1.86
20 42 57 18.8 39.5 53.6 10 22 32 0.45 1.00 1.45
20 38 55 20.8 39.5 57.2 15 20 32 0.75 1.00 1.60
Mean 21.8 39.5 55 21.8 F=39.5 55.0
Kety and Schmidt (1946)
Active- hyper- ventilation 31 52 23.5 39.5 44 59 0.75 1.00
28 55 20.1 39.5 51 87 0.59 1.00
29 43 26.6 39.5 40 70 0.57 1.00
32 41 30.8 39.5 48 56 0.86 1.00
24 44 21.5 39.5 40 69 0.58 1.00
25 43 23.0 39.5 52 79 0.66 1.00
Passive- hyper- ventilation 22 38 22.9 39.5 40 59 0.68 1.00
23 42 21.6 39.5 44 62 0.71 1.00
30 46 25.8 39.5 47 72 0.65 1.00
27 45 23.7 39.5 40 81 0.49 1.00
22 45 19.3 39.5 36 55 0.65 1.00
Mean 26.6 44.9
Kety and Schmidt (1948)
5% CO2 42 50 39.5 47.0 48 65 1.00 1.35
42 47 39.5 44.2 50 67 1.00 1.34
41 48 39.5 46.2 46 75 1.00 1.63
48 54 39.5 44.4 63 90 1.00 1.43
41 46 39.5 44.3 56 80 1.00 1.43
42 53 39.5 49.8 63 141 1.00 2.24
7% CO2 45 60 39.5 52.7 53 135 1.00 2.55
45 58 39.5 50.9 45 90 1.00 2.00
Mean 43.3 52.0
Grand mean ([kPa]) 22.7 (3.03) 39.5 (5.27) 51.5 (6.87) 0.67 1.00 1.71
The arterial PaCO2 and CBF values from three human studies (Kety and Schmidt, 1946, 1948; Ramsay et al., 1993) are shown. The PaCO2 values for hyperventilation
(H) control situation with normocapnia (C) and an experimental period (E) with special gas mixture enriched with 5–7% CO2 are shown in absolute values and relative
(FH/C, FC/C, and FE/C) values normalized to standard average of F=39.5 mm Hg, taken from Ramsay et al. (1993). The CBF values for each situation (H, C, E) are
shown in mL/100 g/min and as fraction of normocapnic flow (H/C, C/C, E/C).
where kr=− 5.251 and B= 10,570. By changing the logarithm
from log10 to the natural logarithm using log10(x)= ln(x)/ln(10)
equation (1) becomes






This simplifies the equation to




where ka= kr/ln(10)=− 2.2805 and B= 10,570. This equation
describes the CO2-induced relative CBF changes compared to the
average baseline CBF and therefore serves as a basis for correction.
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The values 0.42 and 2.31 are the minimum and maximum relative
change the blood flow is predicted to deviate from a normalized
CBF of 1.
To fit this function to human data, we determined the values
of B and ka and the maximum correction for hypercapnia H max,
and the minimum correction for hypocapnia H min. Because the
hypocapnic values of CBF have less variation, H min represents
an average relative decrease to 0.67 of the normocapnic flow. For
hypercapnic values with greater variation of the CBF response, the
theoretical maximum was chosen to be the maximally observed
response of H max= 2.55, i.e., 2.55 times the normocapnic flow.
Given that the function must pass through a normocapnic cor-
rection factor of unity (at the point 39.5,1), B was isolated as a
function of ka,
B = Hmax − 1
1−Hmin 39.5
−ka (4)
This means that the correction factor fC is dependent only on the
parameter constants H min, H max, and the remaining constant ka
fC = Hmin + (Hmax −Hmin)[
1+ B PaCO2ka
] (5)
from which we estimate the remaining parameter ka by regres-
sion such that fC is consistent with the average values for the
hypo- and hypercapnic response. The fitted function is shown
in Figure 1.
The fitted version of equation (5) with fixed human parame-
ters H min, H max, B, and ka is the standard curve used for the
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FIGURE 1 |The fitted function for the correction factor fc. The factor
fC = 0.67+ (2.55− 0.67)/[1+ 2.34× 1011PaCO−6.72 ] and the fractional CBF
values H/C, C/C, and C/E are shown in relation to the relative PaCO2 (pco2)
measure in [mmHg]. The normocapnic points constrain the fit at relative
CBF value C/C= 1 by definition. Single measurements fromTable 1 are
blue, mean values are red (*).
standard baseline CO2 set-point (F) for normocapnia to be at
F = 39.5 mmHg.
Application of CO2 correction
The application of the standard correction factor to an actual
dataset consist of tree main parts:
I) Find the baseline CO2 set-point (PaCO’2)for the study, and
define the scaling factor R = F/PaCO’2 relative to the
standard F = 39.5 mmHg.
II) Scale the measured CO2 value PaCOmeasured2 by R and insert
in equation (8) to find fC.
III) Divide the measured flow (CBFmeasured) by the fC to get the
corrected flow CBFcorrected.
For the application of the correction factor to an actual dataset,
we need to know the baseline set-point (PaCO’2)of average normal
PaCO2 for that dataset. Note that this is possibly different in dif-
ferent subgroups, but was not statistically different in the groups
we studied. Therefore we used a common mean PaCO’2 for both
AD and HC groups. This baseline set-point PaCO’2 is used relative
to the standard CO2 value F = 39.5 mmHg used in the regression
to scale new CO2 values (PaCO
measured
2 ) relative to the standard
CO2 range.
Having chosen the mean reference value PaCO’2 whereby R
becomes R = F/PaCO’2, the correction factor fC for a measured
flow (CBFmeasured) observed at PaCO
measured
2 can be found as a
modified version of equation (5) with normocapnia set at the
PaCO’2 value of the dataset,
fC = Hmin + Hmax −Hmin[
1+ B (R PaCOmeasured2 )ka] (6)
such that when PaCOmeasured2 = PaCO′2, fC= 1, no correction
occurs.
The actual corrected CBF value is now readily found by dividing




For a given normocapnic value of CBF (CBFnorm), the inverse
predicted values for hypercapnia and hypocapnia CBFpredict can
be found by the relationship,
CBFpredict = fC CBFnorm (8)
POSITRON EMISSION TOMOGRAPHY
During a series of PET investigations in which values of
PaCO2 were not deliberately varied, we measured the arterial
PaCO2 tension in samples from a group of healthy age-matched
healthy volunteers (HC, n= 8) and a group of patients with
Alzheimer’s disease (AD, n= 5). The tracers used to determine
rates of CBF and CMRO2, respectively, were [15O]water and
[15O]O2.
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Subjects
Five patients with AD (3 women, 2 men) with an average age
of 64 (SD 7) years and moderately reduced Mini-mental State
Examination (MMSE) scores of 22–25 volunteered to complete
the tomography. The patients were recruited by the local Demen-
tia Clinic and screened by an experienced neurologist for the
presence of probable Dementia of Alzheimer’s Type (DAT). Eight
healthy age-matched HC volunteers with MMSE and CAMCOG
scores in the range of 28–30 with a mean age of 67 (SD= 6)
years served as controls, recruited by public advertisement and
screened with clinical, neurological, and neuropsychological test-
ing including MMSE adapted to Danish (Lolk et al., 2000) to
exclude cognitive impairment. We obtained written informed con-
sent from all subjects to the protocols approved by the Regional
Science Ethics Committee in accordance with the Declarations of
Helsinki.
CBF and CMRO2
All subjects had one or two [15O]water and one or two [15O]O2
emission recordings in the 3D mode of the ECAT High Resolu-
tion Research Tomograph (HRRT, CTI/Siemens, Knoxville, TN,
USA) in a quiet room with the subjects resting in a supine posi-
tion with eyes open. The images were reconstructed with 3D-
OP-OSEM point spread function reconstruction (Varrone et al.,
2009) using 10 iterations and 16 subsets with FWHM at approx-
imately 1.5 mm. The reconstructed images were corrected for
random and scatter events, detector efficiency variations, and dead
time. Tissue attenuation scans were performed using a rotat-
ing [68Ge] source. Dynamic emission recordings lasting 3 min
(21 frames) were initiated upon bolus intravenous injection of
[15O]water (500 MBq) or inhalation of [15O]O2 (1000 MBq).
Catheters (Artflon and Venflon, Becton Dickinson, Swindon, UK)
were inserted in the right radial artery and left cubital vein
and arterial blood radioactivity was measured every half sec-
ond for the duration of the PET scan by an automated blood
sampling system (Allogg AB, Mariefred, Sweden), cross-calibrated
with the tomograph, and then corrected for external delay and
dispersion.
We quantified the CBF as the water clearance from the
blood K H2O1 in units of mL/100 g/min with the linearized two-
compartment model (Blomqvist, 1984) modification of Ohta et al.
(1996) and the Lawson-Hanson non-negative least squares solu-
tion to general least squares functions (Lawson and Hanson,
1974).
We quantified the CMRO2 in units ofµmol/100 g/min from the
oxygen clearance from the blood K O21 by multiplying individual
hemoglobin concentrations with the oxygen clearance obtained
with the same linearized two-compartment model (Blomqvist,
1984) modification of Ohta et al. (1992) and the Lawson-Hanson
non-negative least squares solution to general least squares func-
tions (Lawson and Hanson, 1974). Arterial CO2 tensions were
measured in manually drawn blood samples obtained in relation
to the PET acquisitions with the ABL825flex blood analyzer.
Individual images for each group were averaged after spatial
normalization, to produce average CBF and average CMRO2 val-
ues. To enable direct comparison with the average CBF values, we
scaled the average CMRO2 values back to the K
O2
1 value in units of
mL/100 g/min, using the group mean hemoglobin concentration
Hbmean for each subject.
K O21 = CMRO2 /Hbmean and 1K1 = K H2O1 − K O21 (9)
Statistical difference between AD and HC group means were cal-
culated for cortical values using a two-sample t -test of the null
hypothesis of equal means. The analysis of variance between
groups used the two-sample F-test of the null hypothesis of equal
variances.
TISSUE OXYGEN GRADIENT
In order to estimate the oxygen gradient in the tissue, we combined
measures of CBF and CMRO2 to calculate the capillary oxygen ten-
sion and subsequently the CMRO2 to estimate the mitochondrial
oxygen tension PmitO2 decrease as a function of distance from the
capillaries.
The derivation of the mitochondrial oxygen gradient in the
tissue (Gjedde et al., 2002) proceeded as follows: The decline of
oxygen tension from the capillaries to mitochondria determines
the transport of oxygen and hence defines the rate of oxygen









where L is Krogh’s diffusion coefficient which depends on the
distance from the capillaries, and P
cap
O2
and PmitO2 are the oxygen
tensions in the capillaries and mitochondria, respectively. From
this relationship, we defined the tissue gradient as a function of
the diffusion capacity (Gjedde et al., 2010),








the mitochondrial oxygen tension PmitO2 was plotted as a function




is the average capillary oxygen tension that depends on the




expressed in terms of the half saturation constant of hemoglobin,
P
cap
50 , the Hill coefficient for capillaries h, and the extraction frac-
tion of oxygen EO2 . For a complete derivation please see Chap.
22, pp. 523–549, in Gjedde (2005) and Vafaee and Gjedde (2000,
2004), Gjedde et al. (2005, 2010). This relation yields a formula
that expresses the average capillary oxygen tension as a function
of the oxygen extraction fraction and the hemoglobin oxygen














culated from the extraction fraction EO2 = CMRO2/(CartO2 CBF)
(Gjedde et al., 2005) and by applying standard human values for
P
cap
50 = 27 mmHg and h= 2.7. This formulation of PcapO2 was used
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in equation (11) to express the tissue oxygen tension directly from
the CBF and CMRO2











where CartO2 is the arterial concentration of oxygen, in this case
assumed equal to the hemoglobin concentration for fully saturated
arterial blood.
RESULTS
The results consist of three different parts:
1) The result of fitting the historic data and the parameters for
the human correction factor. Application to subgroup data
previously published.
2) The results of applying the standard correction method to a
new dataset of AD and HC subjects.
3) Evaluation of oxygen gradients in order to explain the CBF
influence on tissue oxygenation in AD.
CORRECTION FOR REACTIVITY TO CO2
To derive the equation that corrects for the PaCO2 variability in
both groups,we adopted arterial PaCO2 and CBF values from three
human studies reported in the literature (Kety and Schmidt, 1946,
1948; Ramsay et al., 1993), as listed in Table 1. These PaCO2 values
refer to the hyperventilation (H), normocapnic (C), and experi-
mental (E) conditions, where specific gas mixtures enriched with
5–7% CO2 yielded both with absolute values in units of mmHg
and values relative to a standard average of 39.5 mmHg, adopted
from Ramsay et al. (1993). The CBF values for each situation
(H, C, E) are given in units of mL/100 g/min and as fractions
of normocapnic flow (H/C, C/C, and E/C).
From the PaCO2 relative to the mean of 39.5 and fractional
CBF values (i.e., fC), we fitted equation (5) to the H/C, C/C, and
E/C response ratios reported in the range of 0.67- to 2.55-fold
the average normal CBF (Figure 1). The parameters of the fit-
ted standard function function 5 were H min= 0.67, H max′ = 2.55,
B= 2.34× 1011, and ka=− 6.7.
In order to illustrate how this parameterized correction can
be applied to individual data-sets with very different CBF group
average and different mean CO2 level, we fitted the historic gray
and white matter data separately using the steps (I), (II), and (III)
previously described. The subgroup set-points used are listed in
Table 2.
As shown in Figure 2 the predicted the CBF in response to
PaCO2 fits each of the subgroups well even though the data mag-
nitudes involved are very different. A similar approach was used for
the average values of regional values reported in Ito et al. (2008),
as shown in Figure 6.
CBF VARIABILITY IN AD AND HEALTHY AGING
Subjects had spontaneous PaCO2 values as high as 45.2 mmHg and
as low as 27.1 mmHg. Only data within the normocapnic range of
35–45 mm Hg was used to determine the normocapnic set-points.
The mean PaCO’2 was 39.6 (SD 2.4) mmHg in the healthy subjects,
Table 2 | Normocapnic CBF measures (historic).
PaCO
′
2 mmHg CBFnorm mL/hg/min
Grey matter 44 60
White matter 40 19
FIGURE 2 | Measured hypocapnic, normocapnic, and hypercapnic
quantitative CBF values in relation to the absolute measured PaCO2
(pco2) in mm Hg. The red values are cortical values taken from Ramsay
et al. (1993) or measurements from Kety and Schmidt (1946, 1948), based
on the nitrous oxide method. The blue values are white matter flow taken
from Ramsay et al. (1993). The points are super-positioned with curves of
the expected CBF values when using the correction function relative to a
mean normocapnic flow.
and 38.3 (SD 0.9) mmHg in the AD patients. These group-wise
normocapnic means were used to determine the CO2 response
curves used for correction for CO2 by the steps (I), (II), and (III)
described in the Methods.
CBF values for the AD and HC groups are reported in Table 3.
Mean CBF was significantly lower in the AD group compared to
the HC group, both with (p< 0.0005) and without (p< 0.005)
correction for CO2. The variation, however, was only significantly
reduced in the AD group when data had been corrected for CO2
differences. The PaCO2 corrections indicated that substantial vari-
ability of CBF stemmed from the PaCO2 effect in both groups.
Figure 3 shows the corresponding values of PaCO2 and CBF for
the two groups. The healthy controls had considerable additional
variation of CBF, which was not related to differences of PaCO2. In
the AD patients, however, the average CBF was substantially lower
and the entire variation was commensurate with the response
predicted by PaCO2.
CBF VARIABILITY AND TISSUE OXYGENATION
To evaluate the extent to which the loss of additional variability
of CBF in the AD patients is explained by uncoupling of CBF
from oxygen metabolism, we determined the difference between
the blood-brain clearances (K 1) of water and oxygen (1K 1), i.e.,
the component of CBF not devoted to the clearance of oxygen.
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AD 45.2 52 37 185
39.4 39 37 149
37.5 38 39 153
38.9 41 40 151
37.7 37 38 160
Mean 39.7 (3.1) 41(6.3)** 38(1.2**)*** 159(15)
Mean
(35–45 mmHg)
38.4 (0.9) 38.6(1.7)*** 39(1.2*)*
HC 39.000 55 56 187
39.225 48 49 190
38.175 55 59 148
27.075 44 62 210
39.000 58 60 200
36.225 59 68 209
42.750 50 43 158
42.825 55 47 154




Group comparisons were done for difference between AD and HC t-test of
means and a f-test was done for difference in variance. The AD had significant
decreased mean and variance after correction for the CO2 effect (***p< 0.0005,
**p<0.005, *p<0.05).
As shown in Figure 4, for healthy controls, the association (non-
primary) cortices of the frontal, occipital, parietal, and temporal
lobes have the highest1K 1 values, while K 1 values in primary sen-
sorimotor cortices were much closer to each other, also indicative
of greater oxygen extraction. However, for the standard deviation
among the HC subjects, rendered as a color-coded map shown
in Figure 4, the higher variability of 1K 1 is evident in occipital,
parietal, and temporal lobes compared to the frontal lobe.
Average capillary oxygen tensions, calculated from equation
(12), declined significantly in the AD patients compared to the
age-matched HC subjects, as shown in Figure 5. In both groups,
the decline of oxygen in the tissue depended on the degree of
non-linear coupling of flow to oxygen consumption, and the
resulting gradients of oxygen tension determined from equation
(13) did not differ significantly between the groups and thus did
not indicate deficient oxygen delivery in AD.
DISCUSSION
GENERAL CO2 CORRECTION METHOD
The method presented here is a practical approach to the cor-
rection of CBF data for changes of PaCO2 that relates individual
measures to the normocapnic mean for an individual or a group.
The correction factor is derived from historical data obtained from
a broad spectrum of studies. The correction is independent of the
absolute flow rates and thus applicable to both grey and white
matter regions of the brain.
The range of PaCO2 values is established by intra-
individual responses to the tomography such as anxiety-induced
FIGURE 3 |The figure shows the measured and predicted CBF values
for AD and healthy subjects in relation to PaCO2 measures. The group
means and SD used for the predictions are from within the normocapnic
range of 35–45 mm Hg. The single SD estimates are based on
(meanpCO2 + 1SDpCO2 , meancbf + 1SDpCO2 ) and (meanpCO2 + 1SDpCO2 ,
meancbf − 1SDpCO2 ).
hyperventilation, and inter-individual and group variations of
PaCO2, and the present approach accounts for all of these
changes. In studies analyzed by general linear model (GLM) sta-
tistics, PaCO2 variation can be factored out as a covariate, but the
procedure considers only the influence on the statistics, not the
magnitude of the corrected flow. The GLM model is not appro-
priate for modeling non-linear relationships. Another approach to
PaCO2 correction is a simple division of the CBF measure with the
PaCO2 values (Ashwal et al., 1991), but the procedure yields a lin-
ear relationship and therefore does not account for the differences
of the CBF/mmHg ratio in hypocapnia compared to hypercapnia.
The result is consistent with hypocapnic reactivity but underesti-
mates the hypercapnic response. Claassen et al. (2007) also applied
a logistic model somewhat similar to the one introduced here.
However it was applied to CBFV data and not CBF data at steady
state, but they showed a good agreement with the logistic shape
even at very high time resolution.
Although the methods of measuring and correcting for the
hemodynamic response to changes of the arterial CO2 tension
vary somewhat, the results of separate studies in man agree to
a considerable extent when interpreted relative to normocap-
nic values, as demonstrated in Figure 1. In this figure, data
extracted from three different human studies are represented.
Data from references Kety and Schmidt (1946) and Kety and
Schmidt (1948) include measures of healthy young men in whom
control values of CBF were determined with the nitrous oxide
method of Kety and Schmidt at normal ambient conditions and
normal breathing. The effects of passive and active hyperven-
tilation provided hypocapnic values for the same subjects. For
hypercapnia, the subjects were exposed to an atmosphere of 21%
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FIGURE 4 | Upper row: Group mean 1K 1 and 1 SD images for the healthy
control subjects as well as a lobe overview, Lower row: Group mean 1K 1
and 1 SD images for the Alzheimer’s patients. For comparison is added in
the third column a calculated image of adding 1 SD of the healthy aged
controls to the 1K 1 magnitude of the AD. Group mean 1K 1 images are
colored using hot-metal color scale (values below 15 mL/100 g/min in gray). 1
SD images are shown in black, blue, and white color scale (values below
5 mL/100 g/min in gray). The lobe overview indicates the position of temporal
lobes in green, occipital lobes in red and parietal lobes in blue. The standard
deviations for AD patients were much lower than for the controls, and the
group difference in 1K 1 possibly could be explained by the loss of variability
in the patients. All images are mapped onto standard brain gray-white matter
surfaces using FACE software from Aalborg University (Eskildsen and
Østergaard, 2006).












































































FIGURE 5 | Oxygen gradient plotted through the tissue. AD
gradients are not significantly below HC gradients, indicating no
shortage of oxygen due to insufficient oxygen delivery. The
assumption here is normal or high capillary density, translated into
diffusion capacity (L), as generally observed in the literature. Capillary
density would have to be significantly reduced to suggest hypoxic
conditions in AD. The capillary oxygen tension is the oxygen tension
for 1/L ; 0.0.
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FIGURE 6 | Regional average CBF values (N=20) of the hypocapnia,
normocapnia, and hypercapnia conditions. The green line is the
estimated CBF based on application of the correction factor to the
normocapnic values of PaCO2 and CBF. The red lines are estimates of CBF
response, 95% confidence, i.e., 1.96 SD from normocapnic values of
PaCO2 and CBF.
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oxygen with 5 or 7% added CO2. Intra-subject CBF measures
with varying CO2 tensions were also reported by Ramsay et al.
(1993). Because they also used PET to determine CBF, we adopted
their mean normocapnic PaCO2 of 39.5 mmHg as the stan-
dard for which the correction factor is unity in the present PET
study.
We modeled the data by the function originally introduced
by Reivich (1964), which included theoretical values for maxi-
mum vasodilatation and -constriction. Although these values are
uncertain in man, the functional relationship obtained with the
parameter values proposed here fits the data well.
In primates, Reivich (1964) found the maximum response to be
42% of the average normal CBF of 49.3 mL/100 g/min for vasocon-
striction and 231% of the average normal CBF for vasodilatation,
corresponding to CO2 tensions of 15 mmHg (2 kPa) and 150 mm
Hg (20 kPa), respectively.
In contrast, in man, measured extremes of PaCO2 are closer to
20 and 60 mmHg (Kety and Schmidt, 1946, 1948; Ramsay et al.,
1993), corresponding to a measured range of response of 44–255%
of the average normal CBF value. As the response in rhesus mon-
keys appears to be less than in humans, a CO2 tension of 60 mmHg
yields a 146% increase of CBF in the monkeys but a 218% increase
in humans, where the same increase is reached at 48 mmHg. In
primates, the sensitivity to CO2 fits a logistic exponential rela-
tionship between carbon dioxide tensions and blood flow, and
we chose to modify this relationship with different parameters
descriptive of the human situation as the overall functional shape
for humans.
Regional variation
The relationship among baseline CBF values and the regional vas-
cular PaCO2 responses recently was revisited by Ito et al. (2008).
Instead of individual numbers, the authors reported regional aver-
age CBF values for 20 subjects at hypo-, normo-, and hypercapnia.
The correction proposed here is in good agreement with cor-
tex values, but cerebellum, thalamus, and putamen had slightly
higher vascular responses than those estimated from the present
correction factor as shown in Figure 6.
CORRECTION FOR AD PATIENTS AND CONTROL SUBJECTS
In the HC group estimates of the vasomotor response to CO2,
the normal flow variation in the 35- to 45-mmHg PaCO2 range is
variable and not explained by the predicted response to CO2. This
discrepancy reflects the number of factors suspected of influencing
CBF. In the AD group, however, we found very little variation in the
normocapnic range and the variability of CBF was closely coupled
to the predicted response. The markedly decreased variability in
AD is consistent with a blunting of the general neurovascular
control unit variability, with largely conserved CO2 regulation.
In a recent MRI study of familiar frontotemporal dementia
(FTD-3) prior to symptom onset, the authors found a significant
decrease of CBF in temporal, occipital, and parietal regions of
familial carriers of the CHMP2B mutation, compared to family
members not carrying the mutation. However, the reduction was
observed only with spin echo sequences sensitive to deoxyhemo-
globin in the capillary bed, suggesting that capillaries rather than
arterioles are the mediators of the decrease, as befits a functional
decline (Lunau et al., 2012). The carriers of the mutation had
a marked loss of CBF variability in the same regions (temporal,
occipital, and parietal regions) found to have declines of the1K 1
estimates in the present study. Although the dementia of that study
is different from the AD studied here, the observation is consistent
with the claim that these regions are particularly important and
vulnerable to the development of early signs of dementia.
Is1K1 important to glucose delivery?
As averaged for each group, the variability of the 1K 1 measure
is related to the BOLD signal obtained with functional MRI,
although it has lower time resolution. For the 1K 1 shown in
Figure 4, much of the variation appears to be lost in the AD
patients, as the1K 1 magnitude is decreased overall but especially
in the occipital, parietal, and temporal lobes. To illustrate how the
loss of variability of the HC group coincides with the loss of 1K 1
for the AD group, we show the result of adding 1 SD of the normal
variation to the low measure of the AD patients. The calculated
AD image strikingly fits the distribution of the 1K 1 estimates of
the age-matched HC controls. Although this has no direct physi-
ological meaning it illustrates that the difference between AD and
HC subjects may be correlated to a loss of CBF variability.
We speculate that this loss may by some means be related to
the loss of ability or necessity of the vasculature to adjust the CBF
to functional demands, especially in the posterior and temporal
regions of the brain.
An important question is whether the lack of variability
expressed as the1K 1 estimate is consistent with an adequate sup-
ply of oxygen, or adequate transport of substrate such as glucose.
As for glucose, recent reports (Vaishnavi et al., 2010; Vlassenko
et al., 2010) suggest that aerobic glycolysis in healthy young adults
is spatially correlated with the depositions of amyloid-β in AD
patients. The authors suggest the existence of a link between high
rates of aerobic glycolysis in young adults and the later develop-
ment of AD pathology. In the present study, the values of1K 1 may
suggest that CBF may normally be uncoupled from metabolism
in the areas with higher aerobic glycolysis indices (Vaishnavi et al.,
2010; Vlassenko et al., 2010) in the age-matched HC group. In the
AD group, however, the loss of the 1K 1 reserve clearly is more
pronounced in the posterior and temporal parts of the brain, as
previously described.
Amyloid beta (Aβ) deposition has been implicated in decreased
glucose transporter-1 levels and hippocampal atrophy in brains of
aged APP/PS1 mice (Hooijmans et al., 2007) at the capillary level
without decreased capillary density. The mechanism could be an
interplay between the upstream Aβ oligomers and neurotrophic
factors such as proNGF/NGF (Schliebs and Arendt, 2011), as neu-
rotrophic factors also have been implicated in the reduction of
GLUT-1 carrier density in the endothelial cells (Farkas and Luiten,
2001). With the exception of putamen and cerebellum, hexose
transporters regionally were found to be about half as numerous
in post mortem AD brains as in control brains (Kalaria and Harik,
1989).
Another indicator that the decrease of 1K 1 is consistent with
a loss of aerobic glycolytic capability, is the reported observa-
tions that the absolute number of mitochondria in endothelial
cells is conserved in AD, although the density per unit volume
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decreased due to endothelial basal membrane swelling or mito-
chondrial shrinkage, both implying impaired blood-brain barrier
(BBB) capacity (Mancardi et al., 1985; Stewart et al., 1992) for
glucose transport but not for the free diffusion of O2. We note
here that microvascular basal membrane pathology in AD with
the accumulation of laminin and heparan sulfate proteoglycans
(HSPGs) in some studies has been linked to the perivascular astro-
cytes (Farkas and Luiten, 2001) which are more glucose dependent
that neurons (Bolaños et al., 2010).
Is1K1 important to oxygen delivery?
For oxygen, the absent decline of capillary density in AD (Richard
et al., 2010) allowed us to compare predicted oxygen gradients
in the groups of AD patients and age-matched HC subjects and
to show that the steady state gradients were nearly identical
(Figure 5), except for the slightly lower capillary oxygen tensions
associated with the higher oxygen extraction fractions of the AD
patients. The lower oxygen tensions reflect the non-linearity of the
relation between blood flow and oxygen consumption (and hence
also the BOLD signal and the inter-individual1K 1) that generally
follows the ratio of oxy- to deoxyhemoglobin and therefore also
elevates the oxygen extraction fraction when oxygen consump-
tion declines, or lowers the extraction when oxygen consump-
tion increases relative to blood flow during functional activation.
Recent findings are consistent with the claim that the resulting
O2 overshoot during activation prevents a sustained drop of oxy-
genation at tissue locations that are remote from the capillaries
(Vafaee et al., 1999; Vafaee and Gjedde, 2000; Gjedde et al., 2005;
Devor et al., 2011). The equivalent gradients of oxygen in the AD
and HC subjects indicate that oxygen delivery at steady state is
adequate for the attenuated functional excursions of brains with
Alzheimer’s disease.
LIMITATIONS
The results could be influenced by changes in blood pressure and
hemoglobin oxygenation (Rasmussen et al., 2007; van Beek et al.,
2012). Also direct effects of CO2 on brain functional variability
itself are possible (Xu et al., 2011).
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